Bronze
As a leadingprecision medicine company, Clinomics Inc. has been introducing next generationdiagnostics tools for personalized molecular diagnosis of cancer and NGS-based analysisservice with sensitive cancer panels based on strong scientific basis for researchcommunity. The liquid biopsy platform, CD-PRIME™ is an optimized microfluidicsplatform for easy and fast enrichment of circulating tumor cells (CTCs) in awhole blood sample (<10 minutes/3ml). CD-PRIME™ provides a unique advantageto investigate Circulating tumor DNA (ctDNA) and CTC from a single tube simultaneouslyminimizing the loss of precious sample.Clinomics distributes cancermolecular Dx products from AmoyDx and liquid biopsy platform from Fluxion Biothrough collaboration and joint R&D with competitive global technologycompanies.
CD-PRIME™ platform provides highly efficient workflow of liquid biopsy for cancer, and is registered as class-1 medical device in FDA. The system also received a CE mark. CD-PRIME™ for CTC analysis performs easy automated protocol of CTC enrichment and staining.